• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.在JAK2V617F阳性和阴性骨髓增殖性肿瘤中,端粒长度严重且相似地缩短。
Leukemia. 2009 Feb;23(2):287-91. doi: 10.1038/leu.2008.319. Epub 2008 Nov 13.
2
Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.骨髓增殖性肿瘤患者 P2Y(12) 途径功能缺陷的临床和实验室意义:一项初步研究。
Acta Haematol. 2013;130(3):181-7. doi: 10.1159/000348413. Epub 2013 Jun 8.
3
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.Ph 阴性慢性骨髓增殖性肿瘤中端粒缩短:与羟基脲治疗无关,是真性红细胞增多症和骨髓纤维化的生物学标志物。
Exp Hematol. 2013 Jul;41(7):627-34. doi: 10.1016/j.exphem.2013.03.007. Epub 2013 Mar 28.
4
Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.JAK2V617F 突变的骨髓增殖性肿瘤中的血栓形成。
Clin Appl Thromb Hemost. 2013 Jul-Aug;19(4):374-81. doi: 10.1177/1076029612453761. Epub 2012 Jul 23.
5
[Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].[骨髓增殖性肿瘤中JAK2V617F突变的研究进展]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1329-33.
6
Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms.费城染色体阴性骨髓增殖性肿瘤中端粒长度和端粒酶活性的动力学。
Leuk Res. 2011 Apr;35(4):459-64. doi: 10.1016/j.leukres.2010.07.042. Epub 2010 Sep 9.
7
Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.Ph阴性骨髓增殖性肿瘤中JAK2V617F突变、等位基因负荷与凝血功能的关系
Hematology. 2017 Jul;22(6):354-360. doi: 10.1080/10245332.2016.1267830. Epub 2016 Dec 15.
8
Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.JAK2V617F和CALR突变的骨髓增殖性肿瘤中CD34+造血祖细胞的特征分析
Leuk Res. 2016 Sep;48:11-5. doi: 10.1016/j.leukres.2016.06.009. Epub 2016 Jun 29.
9
Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden.血栓形成和出血在JAK2V617F等位基因负荷高的骨髓增殖性肿瘤患者中很常见。
Ann Hematol. 2017 Aug;96(8):1297-1302. doi: 10.1007/s00277-017-3040-8. Epub 2017 Jun 6.
10
[A novel quantitative JAK2V617F detection kit: prospective clinical performance study comparing MPN patients and healthy subjects].[一种新型JAK2V617F定量检测试剂盒:比较骨髓增殖性肿瘤患者和健康受试者的前瞻性临床性能研究]
Rinsho Ketsueki. 2018;59(6):669-674. doi: 10.11406/rinketsu.59.669.

引用本文的文献

1
Socio-demographic determinants of myelofibrosis outcomes in an underserved center and the SEER national database.服务不足中心和 SEER 国家数据库中骨髓纤维化结局的社会人口统计学决定因素。
Ann Hematol. 2024 Sep;103(9):3543-3551. doi: 10.1007/s00277-024-05894-7. Epub 2024 Jul 24.
2
Telomerase-targeted therapies in myeloid malignancies.靶向端粒酶治疗髓系恶性肿瘤。
Blood Adv. 2023 Aug 22;7(16):4302-4314. doi: 10.1182/bloodadvances.2023009903.
3
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors.骨髓增殖性肿瘤的靶向治疗:超越JAK抑制剂
Curr Hematol Malig Rep. 2023 Jun;18(3):41-55. doi: 10.1007/s11899-023-00690-y. Epub 2023 Jan 27.
4
Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential.孟德尔随机化支持端粒长度与不确定潜能克隆性造血之间的双向因果关系。
Sci Adv. 2022 Apr 8;8(14):eabl6579. doi: 10.1126/sciadv.abl6579. Epub 2022 Apr 6.
5
Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.与端粒长度和骨髓增生性肿瘤发病风险相关的遗传多态性。
Blood Cancer J. 2020 Sep 1;10(8):89. doi: 10.1038/s41408-020-00356-5.
6
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.真性红细胞增多症后和原发性血小板增多症后骨髓纤维化患者的表型和基因型的性别效应:MYSEC项目的结果
Blood Cancer J. 2018 Sep 21;8(10):89. doi: 10.1038/s41408-018-0128-x.
7
Pharmacotherapy of Myelofibrosis.骨髓纤维化的药物治疗。
Drugs. 2017 Sep;77(14):1549-1563. doi: 10.1007/s40265-017-0797-y.
8
Ruxolitinib therapy and telomere length in myelofibrosis.芦可替尼治疗与骨髓纤维化中的端粒长度
Blood Cancer J. 2016 Oct 7;6(10):e479. doi: 10.1038/bcj.2016.91.
9
TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations.端粒酶逆转录酶基因(TERT)rs2736100基因型与瑞典和中国男性患者群体骨髓增殖性肿瘤的不同风险相关。
Ann Hematol. 2016 Oct;95(11):1825-32. doi: 10.1007/s00277-016-2787-7. Epub 2016 Aug 25.
10
Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.人端粒酶逆转录酶(hTERT)使人类急性早幼粒细胞白血病(AE)前体细胞永生化,从而导致白血病转化。
Oncotarget. 2016 Aug 30;7(35):55939-55950. doi: 10.18632/oncotarget.11093.

本文引用的文献

1
Telomeres, stem cells, and hematology.端粒、干细胞与血液学。
Blood. 2008 Feb 15;111(4):1759-66. doi: 10.1182/blood-2007-09-084913.
2
Concise review: Telomere biology in normal and leukemic hematopoietic stem cells.简明综述:正常及白血病造血干细胞中的端粒生物学
Stem Cells. 2007 Aug;25(8):1853-61. doi: 10.1634/stemcells.2007-0057. Epub 2007 May 17.
3
Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.在转化的JAK2-V617F阳性骨髓增殖性疾病中,白血病原始细胞的JAK2-V617F突变常常呈阴性。
Blood. 2007 Jul 1;110(1):375-9. doi: 10.1182/blood-2006-12-062125. Epub 2007 Mar 15.
4
Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.骨髓增殖性疾病中JAK2的突变:时机、克隆性研究、细胞遗传学关联及在白血病转化中的作用。
Blood. 2006 Nov 15;108(10):3548-55. doi: 10.1182/blood-2005-12-013748. Epub 2006 Jul 27.
5
Telomeres: cancer to human aging.端粒:从癌症到人类衰老
Annu Rev Cell Dev Biol. 2006;22:531-57. doi: 10.1146/annurev.cellbio.22.010305.104518.
6
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.基于X染色体失活的克隆性分析和JAK2V617F定量评估显示,克隆性与真性红细胞增多症(PV)中的JAK2V617F之间存在强关联,但在原发性血小板增多症(ET)/大颗粒淋巴细胞白血病(MMM)中并非如此,并且鉴定出了一部分具有克隆性造血的JAK2V617F阴性ET和MMM患者。
Blood. 2006 May 15;107(10):4139-41. doi: 10.1182/blood-2005-09-3900. Epub 2006 Jan 24.
7
The first molecular details of ALT in human tumor cells.人类肿瘤细胞中ALT的首个分子细节。
Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R191-6. doi: 10.1093/hmg/ddi266.
8
Telomeres and human disease: ageing, cancer and beyond.端粒与人类疾病:衰老、癌症及其他。
Nat Rev Genet. 2005 Aug;6(8):611-22. doi: 10.1038/nrg1656.
9
Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres.
Br J Haematol. 2005 Aug;130(3):391-3. doi: 10.1111/j.1365-2141.2005.05618.x.
10
Telomeres as biomarkers for ageing and age-related diseases.端粒作为衰老及与年龄相关疾病的生物标志物。
Curr Mol Med. 2005 Mar;5(2):197-203. doi: 10.2174/1566524053586545.

在JAK2V617F阳性和阴性骨髓增殖性肿瘤中,端粒长度严重且相似地缩短。

Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

作者信息

Bernard L, Belisle C, Mollica L, Provost S, Roy D-C, Gilliland D G, Levine R L, Busque L

机构信息

Research Centre, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.

出版信息

Leukemia. 2009 Feb;23(2):287-91. doi: 10.1038/leu.2008.319. Epub 2008 Nov 13.

DOI:10.1038/leu.2008.319
PMID:19005480
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4640467/
Abstract

Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by chronic proliferation of hematopoietic progenitors. We studied the telomere length (TL) of 335 MPN patients and 93 gender- and age-matched controls using a quantitative PCR method (relative TL calculated as the ratio of the amount of telomere DNA vs single-copy DNA: T/S ratio). TL was markedly reduced in MPN patients compared with controls (T/S 0.561 vs 0.990, P<0.001). In JAK2V617F MPN patients, TL correlated inversely with allelic burden (P<0.001). Patients homozygous for the mutation (allelic burden 90-100%) had the shortest TL, even when compared with patients with lower allele burdens consistent with a dominant heterozygous population (allelic burden 55-65%) (T/S 0.367 vs 0.497, P=0.037). This suggests that the high degree of proliferation of the MPN clone reduces TL and suggests the possibility that TL shortening may be indicative of progressive genomic instability during MPN progression. The TL of JAK2V617F-negative MPN patients was similar to JAK2V617F-positive counterparts (T/S 0.527 vs 0.507, P=0.603), suggesting that the yet-to-be-discovered causative mutation(s) impact the mutated stem cell similarly to JAK2V617F, and that TL measurement may prove useful in the diagnostic workup of JAK2V617F-negative MPN.

摘要

骨髓增殖性肿瘤(MPNs)是一类克隆性干细胞疾病,其特征为造血祖细胞的慢性增殖。我们采用定量PCR方法(相对端粒长度通过端粒DNA与单拷贝DNA量的比值计算:T/S比值)研究了335例MPN患者及93例性别和年龄匹配的对照者的端粒长度(TL)。与对照组相比,MPN患者的TL显著缩短(T/S 0.561对0.990,P<0.001)。在JAK2V617F MPN患者中,TL与等位基因负担呈负相关(P<0.001)。该突变纯合子患者(等位基因负担90 - 100%)的TL最短,即便与等位基因负担较低的显性杂合子人群患者(等位基因负担55 - 65%)相比也是如此(T/S 0.367对0.497,P = 0.037)。这表明MPN克隆的高度增殖会缩短TL,并提示在MPN进展过程中端粒缩短可能预示着逐渐增加的基因组不稳定性。JAK2V617F阴性MPN患者的TL与JAK2V617F阳性患者相似(T/S 0.527对0.507,P = 0.603),这表明尚未发现的致病突变对突变干细胞的影响与JAK2V617F类似,并且端粒长度测量可能在JAK2V617F阴性MPN的诊断检查中具有实用价值。